Immune checkpoint inhibitor (ICI) therapy has been revolutionary for patients with non–small cell lung cancer (NSCLC), with anti–PD-1/PD-L1 regimens becoming a cornerstone of treatment (1–3). This evidence concerns the gene CD274 and non-small cell lung carcinoma.